Deforolimus is a selective FRAP (mTOR) inhibitor (IC50 of 0.2 nM), used to treat HT-1080 cells induces a dose-dependent inhibition of both S6 and 4E-BP1 phosphorylation, with IC50 of 0.2 nM and 5.6 nM, respectively, and leads to a decrease in cell size, a
Storage Temp
Store at -20°C
Shipped In
Ice chest + Ice pads
Grade
Moligand™
Action Type
INHIBITOR
Mechanism of action
Inhibitor of mechanistic target of rapamycin kinase
1.Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F et al.. (2011) Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.. Mol Cancer Ther, 10 (6):(1059-71). [PMID:21482695]
2.Ray-Coquard I, Le Cesne A. (2012) A role for maintenance therapy in managing sarcoma.. Cancer Treat Rev, 38 (5):(368-78). [PMID:21843915]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
K2212177